Laurus Labs' margin jump came mostly from lower research spending, not its CDMO arm

Laurus Labs reported an EBITDA margin of 34.5% for the September 2026 quarter, 2.7 points higher than the quarter before. EBITDA is profit before interest, tax, depreciation and amortisation. The company plans to spend ₹3,000 crore on new plant over two years, including capacity for its contract development and manufacturing (CDMO) arm, which makes drug ingredients to order for other pharmaceutical companies. Last quarter's gains in sales and margin, though, came mostly from elsewhere.

Sales rose ₹180 crore from the quarter before. The CDMO business supplied little of it; affordable medicines, the generics business that includes HIV drugs, supplied most, and Laurus Bio, the fermentation unit, slipped. Asked what drove the rise, the chief financial officer also credited most of it to affordable medicines rather than CDMO.

None of this means the CDMO business is shrinking. Its sales were 86% higher than a year earlier, and its big step had come in the quarter before. Last quarter added only ₹40 crore, about 5%, to that level. Management said there were no one-off orders in the quarter and that it saw no risk of customers running down stocks, citing its visibility on orders.

If the mix did not shift toward CDMO, something else lifted the margin. Gross margin, which is sales less the cost of materials, barely moved, so the gain came from costs further down. Research spending is the clearest candidate. It took 5.8% of revenue in the quarter before, when, the chief financial officer said, the company filed some applications to sell generic drugs in the US. Calculated from that figure, the company's rounded first-half share and the reported sales, last quarter's research bill comes to about 2.9% of revenue. Add it back and the margin before research was almost the same in both quarters: on this arithmetic, lower research spending explains the whole gain.

Management sees it differently. The chief executive said the improvement was "not just to lower R&D cost, but higher operational leverage." The rounded figures leave room for some of that, and better margins inside the generics business could also have played a part. What the numbers do show is that last quarter's research share sat well below the full-year guide of a share similar to last year's 4.1%, so a return to that level would take back part of the gain. The commitment management repeated is an EBITDA margin above 30%.

The spending, meanwhile, is running. The company invested ₹864 crore in the first half, and the chief executive said the two-year plan still held, with spending at about the same annual pace in later years. On the balance sheet, capital work in progress, which is plant under construction and not yet earning, reached ₹1,282 crore at the end of the half, about two-thirds more than six months earlier, while finished fixed assets stayed flat.

Management dates the returns after this year. The new commercial-scale block for peptides, a growing class of drug molecules, is commissioned; customer validation batches are 12 to 18 months away, the head of CDMO said, and the head of CDMO expects commercial revenue from some of this capacity around 2029. Laurus Bio's new fermentation block will run trials late in this financial year, with commercial supplies possibly from the first quarter of FY28.

The company is paying for this from its own cash flow and modest borrowing. The ratio of net debt to EBITDA fell to about 1.02 from the quarter before, and the chief financial officer said the company had chosen growth spending over free cash flow. A holder therefore owns a business whose margin gain last quarter came largely from a lighter research bill, whose growth over the quarter came from generics, and whose new capacity is meant to pay mostly after this year. The research share against the full-year guide and CDMO sales against last quarter's level are the figures that will show which reading holds.